Matthew Dowling

Matthew Dowling, Ph.D., is the Chief Scientific Officer and Director at Medcura, Inc. He has a robust academic and professional background in bioengineering and chemical engineering.

Education and Early Career

Dowling completed his undergraduate studies in Chemical Engineering at the University of Notre Dame, graduating in 2004. He then pursued a Ph.D. in Bioengineering at the University of Maryland, where he was awarded the Fischell Fellowship for his innovative work in drug delivery systems. His doctoral research focused on chitosan-based self-assembled materials for wound treatment, earning him the Dean’s Doctoral Research Award from the UMD Clark School of Engineering.12

Professional Achievements

Since co-founding Medcura, Dowling has played a pivotal role in developing its core technology platform, which focuses on hemostatic and wound care solutions. Under his leadership, Medcura has secured approximately $10 million in non-dilutive grant funding, leading to five FDA clearances, two Breakthrough Device Designations, and the issuance of 28 patents. He has also published over ten peer-reviewed articles in high-impact journals.12

Before Medcura, Dowling served as the CEO of Remedium Technologies, where he was instrumental in fundraising and developing wound care technologies. His work has garnered media attention, including features on the BBC program "Brave New World with Stephen Hawking" and various national outlets.23

Current Role

In his current position at Medcura, which he has held since November 2019, Dowling continues to drive innovation and regulatory advancements in medical technology, particularly in the realm of wound care.34